Skip to content

Immunovant, Inc. IMVT Prepaid & Other Current

Prepaid & Other Current at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$4.82B+17.8%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$17.55M+92.5%
TG Therapeutics logo
TG TherapeuticsTGTX
$51.46M+152%
Roivant Sciences logo
Roivant SciencesROIV
$105.32M-6.9%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s prepaid & other current?
Immunovant, Inc. (IMVT) reported prepaid & other current of $42.76M in Q1 2026.
How has Immunovant, Inc.'s prepaid & other current changed year-over-year?
Immunovant, Inc.'s prepaid & other current decreased by 16.4% year-over-year, from $51.18M to $42.76M.
What is the long-term trend for Immunovant, Inc.'s prepaid & other current?
Over 5 years (2021 to 2026), Immunovant, Inc.'s prepaid & other current has grown at a 40.8% compound annual growth rate (CAGR), from $7.72M to $42.76M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.